Form 4: Lineage Cell Therapeutics Director Acquires 75,000 Stock Options
SEC Form 4 Filing
Director Dipti Amin acquired 75,000 stock options in Lineage Cell Therapeutics on July 1, 2024, according to a Form 4 filing.
Summary
- Dipti Amin, a director of Lineage Cell Therapeutics, acquired 75,000 stock options on July 1, 2024.
- The options have an exercise price of $0.9541.
- The options will vest and become exercisable on July 1, 2025, contingent upon continuous service with the issuer.
- The options expire on July 1, 2034.
- Following the transaction, Dipti Amin directly owns 75,000 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing reflects insider activity, which is common in publicly traded companies. Monitoring such filings can provide insights into management's perspective on the company's future prospects.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: acquisition of stock options. |
| 07/01/2025 | Vesting date for the stock options, subject to continuous service. |
| 07/01/2034 | Expiration date of the stock options. |
| 07/03/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.